Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACTN in Myelodysplastic Syndromes
NCT03258359Phase 1Unknown
- Sponsor
- PersImmune
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in myelodysplastic syndrome (MDS), sponsored by PersImmune. Primary endpoint: Acute and subacute toxicities and Adverse Events at 4 weeks. Status: unknown.
02
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03258359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258359.